Moberg Pharma AB (MB8.MU)
- PR Newswire
Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%
("Moberg Pharma" or the "Company") announces that 17,776,856 warrants of series 2023:1 ("TO 2") were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%. As announced by the Company on June 11th, 2024, subscription and top guarantee commitments had been made for TO 2, free of charge, with certain external professional investors, and today the board of directors has resolved on a directed is
- PR Newswire
Moberg Pharma has secured exercise of warrants and entered into a top guarantee free of charge
Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") has today received subscription intentions, subscription commitments and top guarantee commitments totaling approximately SEK 113.5 million, related to the warrants of series 2023:1 ("TO 2"), from a few external professional investors and the Company's largest shareholder, Östersjöstiftelsen (The Baltic Sea Foundation).
- PR Newswire
MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication
Moberg Pharma ABs (OMX: MOB) marker partner in Sweden - Allderma AB, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals - has now launched sales of MOB-015 under the Terclara® brand. The interest among pharmacies has been significant for Moberg Pharma's medication against nail fungus.
